Symbios Technologies LLC.
Symbios Technologies is a world-leading developer of dynamic aqueous plasma technology platforms for water treatment, specialty manufacturing, and biotherapeutic applications. The privately held company was founded in January 2008 and is headquartered in Fort Collins, Colorado at the Colorado State University (CSU) Research Innovation Center within the Infectious Disease Research Center (IDRC) on the CSU Foothills Campus. Initial technology development and vetting was performed at the University of Wisconsin, Colorado State University, and the U.S. Naval Research Laboratory. Currently, the TPR is being advanced by Symbios under Phase II Small Business and Innovation Research (SBIR) grant support from the U.S. National Science Foundation (NSF), National Institute of Health (NIH), joint development agreements, and strategic funding with previous funding including the U.S. Department of Energy (DOE) and other partners.
Find locations served, office locations
- Business Type:
- Industry Type:
- Water Treatment
- Market Focus:
- Internationally (various countries)
- Year Founded:
- $1,000,000 US - $10,000,000 US
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Overall, Symbios Technologies is commercializing its disruptive advanced low-cost aqueous plasma oxidation technology, the Symbios Tubular Plasma Reactor4000™ (TPR4000™), to protect human health, preserve the environment, and clean water as well as improve production economics and sustainability.
Bioscience applications of the technology include the production of therapeutic solutions for oncology and virus treatment and disinfection applications in healthcare via bioactive liquid chemistries. The TPR4000 is well suited for the specialty manufacturing of anti-infective small molecule compounds for wound-healing applications in the plasma medicine field.
The Symbios TPR4000 also has applicability as an efficient and cost-effective water treatment technology to aggressively destroy organics and disinfect biologicals for many applications related to purification, sanitation, and clean-in-place. Such applications include, food & beverage processing, pharmaceutical manufacturing, hydraulic fracturing flow back & produced water treatment for oil & gas, power plant cooling tower water treatment, industrial & municipal wastewater treatment, and other specialty treatment of waters from industrial operations for recycling, reuse, and/or discharge.
Symbios Technologies’ customers vary widely and come from multiple disciplines driven by an overwhelming need for advanced water treatment technologies as clean water becomes a more precious resource.
For manufacturing applications, process waters must meet exacting requirements for customer and regulatory acceptance of the finished product. Produced water from the manufacturing process can be contaminated with a range of hazardous compounds and microbes that must be adequately treated before the waters can be discharged into the environment, highlighting the need for more sustainable and green water treatment practices that have minimal chemical reagent and power usage requirements.
Utility water treatment applications encompass markets in both the private and public sector, ranging from municipal to household to industrial treatment for power plant cooling towers. In the oil & gas and other similar industries, the need for enhanced methods for the treatment of produced waters is critical to increase recycling and reuse.
The biosciences field is addressing an overwhelming public health burden relating to hospital-acquired infections, where advanced disinfectant methods are needed. Additionally, the promise for aqueous plasma chemotherapeutics as an advanced cancer treatment with less toxicity and fewer side effects addresses a severe deficiency in the medical community.
The Symbios Tubular Plasma Reactor™ (TPR™) has demonstrated better cost, efficacy, and sustainability potential in all of these markets and represents an important alternative to current solutions that are plagued with severe deficiencies.